GUILMAIN MICHELINE DR MED GENBusiness Directories,Company Directories

Company Name: Corporate Name:	GUILMAIN MICHELINE DR MED GEN
Company Title:
Company Description:
Keywords to Search:
Company Address:	2424 Boul Lapiniere,BROSSARD,QC,Canada
ZIP Code: Postal Code:	J4Z
Telephone Number:	4506789033
Fax Number:
Website:
Email:
USA SIC Code(Standard Industrial Classification Code):	54660
USA SIC Description:	CLINICS & MEDICAL CENTERS
Number of Employees:
Sales Amount:	$1 to 2.5 million
Credit History: Credit Report:	Good
Contact Person:
Remove my name

Company Directories & Business Directories

copy and paste this google map to your website or blog!

Press copy button and paste into your blog or website.
(Please switch to 'HTML' mode when posting into your blog. Examples:
WordPress Example, Blogger Example)

Input Form:Deal with this potential dealer,buyer,seller,supplier,manufacturer,exporter,importer

(Any information to deal,buy, sell, quote for products or service)

Previous company profile:
GULTRAN INC
GUITEL
GUIMOND & ASSOCIE INC COMPTABLES AGRE

Next company profile:
GUILMAIN MAURICE MICHELINE DRE
GUILLEVIN INTERNATIONAL INC
GUILLAUME VIGNAL

Company News:

ASCO 2025: Key Highlights in Advanced Lung Cancer - Medscape
In extensive-stage small cell lung cancer, tarlatamab demonstrated superiority over chemotherapy in the DeLLphi-304 trial, with favorable patient-reported outcomes including improved cough and
Is It Worth Adding Chemo to ICI for NSCLC in Older Adults?
Immune checkpoint inhibitors (ICI) are a cornerstone of non-small cell lung cancer (NSCLC) treatment, but it’s not clear whether adding chemotherapy to ICI — a common practice with younger
Advanced Non–Small Cell Lung Cancer Updates From ASCO 2024 - Medscape
Practice-changing studies in advanced non-small cell lung cancer presented at ASCO 2024 are reviewed by Dr Ticiana Leal, including the phase 3 LAURA and PALOMA-3 studies and a 5-year update of CROWN
Two Lung Cancer Drugs Recommended by EMA - Medscape
Two kinase inhibitors have been recommended by the European Medicines Agency for the treatment of non-small cell lung cancer
Why a New Inhalable Lung Cancer Treatment Is So Promising
Study showed that exosomes (tiny spheres released by cells) can deliver potent immunotherapy to lung cancer tumors
Potential Drivers of LCINS - Medscape
An American Cancer Society expert urges clinicians to advocate for action in the healthcare industry to help combat climate change and its effects on lung cancer incidence
Changes in the Treatment Landscape of Early-Stage Non–Small Cell Lung . . .
Narjust Florez, MD, reflects on the significant changes in the treatment landscape of early-stage non-small cell lung cancer in recent years
Zenocutuzumab Effective Against NRG1 Fusion Cancers - Medscape
The bispecific antibody shows particularly promising results in non–small cell lung cancer (NSCLC) and pancreatic cancer patients, with responses lasting a median of 11 1 months
The Landscape of EGFR Pathways and Personalized Management of Non-small . . .
The -216T allele is preferentially amplified in human lung cancer specimens and cancer cell lines
Early Detection and Screening of Lung Cancer - Page 2 - Medscape
The rationale for developing effective lung cancer screening stems from the fact that lung cancer causes 1 3 million deaths worldwide each year and accounts for more cancer deaths than breast